

Konica Minolta, Inc. 2nd Quarter/FY2024 ending in March 2025 Consolidated Financial Results


Toshimitsu Taiko

President and CEO

Three months(3M): July 1, 2024 - September 30, 2024

Six months(6M): April 1, 2024 - September 30, 2024

- Announced on November 5, 2024 -



Today's Summary



FY24 6M Results and Full-Year Forecasts

- First Half: Significant increase in business contribution profit*
 Improved free cash flow
- Full-Year: Downward revision of operating profit incorporating measures for business selection and concentration and risk of impairment loss Unchanged net profit incorporating gain from all share transfer of Ambry

FY24 6M results

Business Contribution Profit

17.8 billion (YoY +¥15.5 billion)

FCF

16.7 billion (YoY +¥7.3 billion)

Medium-term Business Plan | Progress

- Strengthening business profitability:
 Stabilized profitability of office unit and earnings growth of Professional Print Decision to end production at a manufacturing subsidiary in Wuxi China
- Business selection and concentration:
 Concluded agreement to transfer all shares of Ambry in Precision Medicine
- Global structural reform: Progress ahead of schedule

Business Contribution Profit Ratio

Company overall 3.1% (YoY +2.6 pt)

Office 7.9% Professional Print 4.6% (YoY +2.4 pt) (YoY +1.7 pt)

Medium-term Business Plan | Issues

- Strengthening business profitability: Earnings deterioration in sensing, performance materials and healthcare unit
- Reinforcement of financial foundation:
 Worsening in finance income & loss(foreign exchange loss)
 Continued high tax expenses

Revenue

Industry

60.4 billion (YoY -¥1.3 billion)

Net Profit

Company overall

-10.7 billion (YoY -¥6.2 billion)

FY2024 6M PERFORMANCE OVERVIEW



FY2024 6M Performance | Summary



Revenue: Increased

Gross profit: Improved profit ratio

Business contribution profit*:

Contributed by profit increase of office/production print, loss reduction from non-focused/direction-changing businesses

Operating profit:


Recorded structure improvement expenses of ¥16.4 billion(incl. ¥12.0 billion for global structural reforms, ending production of factory in Wuxi and selection and concentration of DW-DX unit and other factors)

• Profit attributable to owners of the Company: Loss due to worsening in finance income & loss(incl. ¥4.6 billion foreign exchange loss), continued high tax expenses

	FY23 6M	FY24 6M	YoY	w/o FOREX	FY23 Q2	FY24 Q2	YoY	w/o FOREX
Revenue	552.8	583.7	+6%	-1%	286.4	297.5	+4%	+0%
Gross Profit	237.2	260.7	+10%	+2%	125.3	134.3	+7%	+2%
Gross Profit ratio	42.9%	44.7%	+1.7pt		43.8%	45.1%	+1.4pt	
SG & A	235.0	242.9	+3%	-2%	119.0	118.0	-1%	-3%
Business Contribution Profit	2.3	17.8	+679%	+364%	6.4	16.2	+154%	+107%
Operating Profit	0.8	-0.7	-	-	5.2	-0.3	-	_
Profit attributable to owners of the Company	-4.5	-10.7	-		1.1	-7.3	-	
FCF	9.4	16.7	+78%		20.2	25.0	+23%	
FOREX [Yen]								
USD	141.00	152.63	+11.63		144.62	149.38	+4.76	
EUR	153.39	165.95	+12.56		157.30	164.01	+6.71	
RMB	19.75	21.15	+1.40		19.94	20.82	+0.88	

FY2024 6M Performance | Increase/Decrease Factors of Operating Profit and Business Contribution Profit Structural reform effect Structural reform





		actual	amount =			Incre	ease /deci	rease am	ount -			actual	amount	
	FY23 6M Operating Profit	Structural reform improvement cost	Other income and expenses	FY23 6M Business Contribution Profit	FOREX impact	Sales	Production • SCM	Personnel expenses	Structural reform effect	Other SG&A expenses	FY24 6M Business Contribution Profit	Structural reform improvement cost	Other income and expenses	FY24 6M Operating Profit
Digital Workplace	10.0	-0.5	-0.2	10.7	+3.5	-0.0	+1.5	-0.3	+1.7	+2.0	19.1	-12.9	0.4	6.6
Professional Print	3.7	-	0.0	3.6	+2.8	+2.2	-0.2	-0.8	+0.4	-1.5	6.5	-1.7	0.1	4.9
Industry	7.6	-	-0.5	8.1	+0.7	-2.4	+0.2	+0.0	+0.2	+0.6	7.5	-0.5	0.2	7.2
Imaging Solutions	-3.5	-	-0.0	-3.5	+0.0	-1.4	-	+0.0	+0.3	-0.4	-5.0	-0.5	-0.4	-5.9
Precision Medicine	-5.2	-0.1	-0.0	-5.0	+0.1	+2.9	-	+3.9	* -	-0.5	1.4	-0.0	-1.2	0.2
Corporate, etc.	-11.8	-0.2	0.1	-11.7	+0.0	+0.2	-	+0.2	-	-0.5	-11.8	-0.7	-1.2	-13.8
Company overall	0.8	-0.8	-0.7	2.3	+7.2	+1.5	+1.6	+3.0	+2.6	-0.4	17.8	-16.4	-2.1	-0.7

^{*} Includes personnel expenses reduction by transfer of Invicro

FY2024 6M Performance | Revenue & Profit by Segment



Revenue	FY23 6M	FY24 6M	YoY	w/o FOREX	FY23 Q2	FY24 Q2	YoY	w/o FOREX
Digital Workplace	294.5	307.6	+4%	-2%	151.2	155.6	+3%	-1%
Professional Print	124.0	139.1	+12%	+5%	63.8	71.4	+12%	+8%
Industry	61.7	60.4	-2%	-7%	32.0	29.5	-8%	-11%
Imaging Solutions	48.5	50.4	+4%	+0%	26.7	27.6	+3%	+2%
Precision Medicine	23.8	25.8	+9%	+1%	12.4	13.3	+7%	+4%
Corporate, etc.	0.3	0.3	+8%	+8%	0.2	0.1	-2%	-2%
Company overall	552.8	583.7	+6%	-1%	286.4	297.5	+4%	+0%

Business Contribution Profit	FY23 6M	ratio	FY24 6M	ratio	YoY	w/o FOREX	FY23 Q2	ratio	FY24 Q2	ratio	YoY	w/o FOREX
Digital Workplace	10.7	4%	19.1	6%	+78%	+45%	8.4	6%	12.3	8%	+47%	+32%
Professional Print	3.6	1%	6.5	5%	+80%	+2%	2.8	2%	4.8	7%	+68%	+26%
Industry	8.1	3%	7.5	12%	-7%	-19%	4.3	3%	3.8	13%	-12%	-23%
Imaging Solutions	-3.5	-	-5.0	-	-	-	-0.8	-	-0.9	-	-	-
Precision Medicine	-5.0	-	1.4	5%	-	-	-2.1	-	1.6	12%	-	-
Corporate, etc.	-11.7	-	-11.8	-	-		-6.3	-	-5.3	-	-	_
Company overall	2.3	1%	17.8	3%	+679%	+364%	6.4	4%	16.2	5%	+154%	+107%

Operating Profit	FY23 6M	ratio	FY24 6M	ratio	YoY	w/o FOREX	FY23 Q2	ratio	FY24 Q2	ratio	YoY	w/o FOREX
Digital Workplace	10.0	3%	6.6	2%	-34%	-64%	8.0	5%	2.1	1%	-74%	-85%
Professional Print	3.7	1%	4.9	4%	+34%	-40%	2.7	2%	3.3	5%	+19%	-22%
Industry	7.6	3%	7.2	12%	-5%	-18%	3.7	2%	4.1	14%	+11%	+0%
Imaging Solutions	-3.5	-	-5.9	-	-	-	-0.8	-	-1.7	-	-	-
Precision Medicine	-5.2	-	0.2	1%	-	-	-2.1	-	-1.2	-	-	-
Corporate, etc.	-11.8	-	-13.8	-	-		-6.4	-	-7.0	-	-	_
Company overall	0.8	0%	-0.7	-	-		5.2	3%	-0.3	-	-	-


FY2024 6M Performance | Business Trends of Industry

FY23 6M

FY24 6M




(YoY)



FY2024 6M Performance | Business Trends of Professional Print



[¥ billions]



Revenue

(YoY)

Production
print
+7.6

[Revenue]	FY24 6M	w/o FOREX	FY24 Q2	w/o FOREX
Hardware	+9%	+2%	+7%	+4%
Non-hard	+10%	+2%	+7%	+3%

_[Units]		
Color models	-1% (HPP+37%)	+2% (HPP+28%)
Monochrome models	-10%	-7%

- (+) Non-hard: Strong in the U.S. and India
- (+) Hardware: drupa effect, volume increase of HPPs

Industrial print +3.2

- (+) Non-hard: Increase in sales in all areas due to increase in number of printing machines in operation
- (+) Hardware: drupa effect, volume increase of inkjet, label, and embellishment

Business Contribution Profit

Professional Print Business +2.9


- (+) Production print: Volume increase and FOREX impact
- (+) Industrial print: Decrease in loss due to volume increase and FOREX

FY2024 6M Performance | Business Trends of Digital Workplace

Povonuo



(VaV)



	[Value]	FY24 6 M	w/o FOREX	FY24 Q2	w/o FOREX
	Hardware	+2%	-4%	+6%	+2%
	Non-hard	+6%	-0%	+3%	-1%
Office	[Units]		.,		
+10.8	A3 color m	odels -6°	%	-30	%
	A3 monoch models	nrome +5°	%	+9	%
		d: Decrease in Ja acrease in India	=		pe, and

Business Contribution Profit

Digital
Workplace
Business
+8.4

DW-DX

+2.4

(+) Office: Production cost reduction and SG&A control including structural reform effect

(+) Operation optimizing services*1: Strong in Japan, the

(+) AI SaaS services*2 by industry: Strong in Japan

(+) DW-DX: Decreased loss due to gross profit increase and SG&A control, etc.

U.S., and Europe


^{*1} Operation optimizing services: Services that provides business content management and business process management

^{*2} AI SaaS services: Services developed in-house such as AI-based interpretation, knowledge management, and learning support

FY2024 6M Performance | Business Trends of Imaging Solutions



[¥ billions]



Solutions Business

-1.5

- (+) Visual solutions: Turned profitable
- (+) Imaging-IoT solutions, etc.*: SG&A expenses reduction

6.5

-3.5

1.8

FY24 6M

6.7

-5.0

2.3

in DR in Japan and film and the subsequent decrease in production efficiency

^{*} FORXAI and QOL solutions, which were included in CO, etc. in FY2023, have been added FORXAI: Business unit that develops a company-wide common technology platform centered on AI technology OOL solutions: Business unit that develops monitoring solutions for care facilities

FY23 6M

MEDIUM-TERM BUSINESS PLAN PROGRESS



Precision Medicine Business



 Agreement concluded to transfer all shares of Ambry Genetics, a U.S. genetic testing company, to Tempus AI (November 5, 2024)

Tempus AI	Location: Chicago, the U.S. Year of Establishment: 2015
Tempus AI	Business description: Providing precision medical technology utilizing data and AI

Transfer price and schedule

Transfer price	USD600 million (approximately ¥84.0 billion), of which USD375 million will be paid in cash, USD225 million will be paid in Tempus Type A common stock*
Transfer date	FY24 H2 (planned)

^{*}Of the Tempus Type A common stock of USD225 million, USD125 million portion will be available for selling after completing the registration process, and USD100 million portion is subject to a 12-month lock-up period.

Impact on Profit and Loss

- The Precision medicine business will be classified as a discontinued operation. It is excluded from revenue, business contribution profit, and operating profit.
- The ¥41.0 billion* gain from the transfer of the shares is expected to be recorded on net profit as a profit from discontinued operation in FY24 H2.

Impact of classification as discontinued operation on FY2024 full-year consolidated earnings


Revenue	-¥46.0 billion
Business contribution profit	+¥4.0 billion
Operating profit	+¥4.0 billion
Profit attributable to owners of the Company	Approx. +¥41.0 billion

^{*} The gain from transfer is calculated by deducting net assets, debt from the Company, transaction costs from the corporate value, and adding realized profit and loss on exchange differences on translation of foreign operations.

^{*} The final amount of a gain or loss on the share transfer might change depending on the future stock price, foreign exchange rate fluctuations, and other factors.

Medium-term Business Plan Progress | Non-focused business and Direction-changing business





Progress in FY24 6M

Non-focused business

Accelerate "business selection and concentration"

Precision Medicine

Business contribution profit improved by ¥6.4 billion
 Strong in genetic testing service business

Direction-changing business

Narrowed down region/country and business area Execution started, progressing as planned

DW-DX

- Implemented "business selection and concentration" and improved profit ratio in continuing areas
 - Completed transfer of MWA Intelligence, the U.S. Sales Company's ERP Solutions Division (June)
 - Completed transfer of HydraCloud, the IT infrastructure construction and operation business of Norwegian sales company (June)
 - Completed transfer of French IT training business (September)

Imaging-IoT solutions


Review of sales resources and strengthening of solution sales

Progress in Global Structural Reform and Business Selection and Concentration



Global structural reform progress ahead of schedule and continue our initiatives to improve productivity

Global structural reform



Number of Group employees: Trend/Plan

	End of Mar. 2024	End of Sept. 2024	End of Mar. 2025 (plan)					
Cumulative reduction number (incl. temporary and contract workers)								
Structural reform		1,597 people	Approx. 2,400 people					
Business selection and concentration		511 people						
Group employees (regular employees)	40,015 people	38,516 people	<37,000 people					

Progress toward Medium- to Long-Term Growth | Industry(Optical Components for Semiconductor Manufacturing Equipment)



Business expansion by capturing changes in the supply chain and increasing our share within customer through strengthening relationships

Policies

(from the FY2023 Industry Business Briefing)

Reinforcement of development and production systems

- **1** Strengthening relationships with customers
- **Introducing next-generation technology**
- Strengthening systems through reorganization and securing human capitals




Investment for mid-to long-term growth

- Investment in capital expenditure at scale of billions of ven
- **R&D** investment to adopt next-generation technologies while also optimize existing technologies

Progress

Progress in pipeline expansion and preparation for growth

- ① Expanding orders in the middle-end field (VIS/UV*1) for a specific customer through customization and stable supply
- 2 Introducing non-contact polishing technology to standardize polishing technology and improve surface precision
- 3 Planning human capital investment to increase production capacity



^{*1} Wavelength range of light sources. As the wavelength becomes shorter in the order of VIS(visible), UV(ultraviolet), DUV(deep ultraviolet), VUV(vacuum ultraviolet), it is used for forming and inspecting, etc. finer semiconductor circuit patterns.

Cost Structure Reform | Progress in B/S Improvement




Progress in asset reduction through reducing operating receivables and business transfer and interest-bearing debt reduction

FY24 Q2 results (compared to the end of FY23)

Total assets: -\(\frac{4}{64}.1\) billion, \(\widetilde{w}\) o FOREX impact -\(\frac{4}{36}.9\) billion

- Trade receivables: -\footnote{\text{17.4}} billion, \text{ w/o FOREX impact -\footnote{\text{49.0}} billion
- Inventories: -¥2.8 billion, w/o FOREX impact +¥1.7 billion
- Assets held for sale: -24.7billion(Invicro and other factors)


Interest-bearing liabilities: -¥17.1 billion



Reinforcement of Financial Foundation | Inventories and Operating Cash Flow



Reduction and turnover improvement of inventories year-on-year





Drojects that have achieved results.

Towards the second half of the Medium-term Business Plan, accelerate the completion of business selection and concentration, return to growth in strengthening businesses and reinforcement of financial foundation

		FY23-FY24 6M	Projects that have achieved results Projects that are behind schedule Projects currently underway			
	Utilizing third-party capital for non-focused businesses	 Precision medicine: Concluded agreemer Marketing services: Exclusion of domesti 	manufacturing subsidiary (closing not completed)			
Strengthening	Re-establishing the strategic direction of direction-changing businesses	 DW-DX: Reduction in losses through reorganization Imaging-IoT solutions: Reduction in losses through review of sales resources 				
business profitability	Expanding revenue for Business Technologies Business	 Office: Profitability improvement Business Technologies: Business alliance with FUJIFILM Business Innovation Corp. Business Technologies: Decision to end production of factory in Wuxi, China 				
	Groundwork to establish a growth foundation	Strengthening business: Profitability deteriorating in fundamental fields (Light source color displays films, Y-ray DP)				
	Global structural reform	 Executing plans ahead of schedule 				
Reinforcing revenue foundation	Strengthening the financial foundation	 Achieve positive FCF by reducing working capital Reduce interest-bearing liabilities Deterioration of finance income & loss due to foreign exchange loss and increase expenses resulted in net loss (FY24 H1) 				

FY2024 EARNINGS FORECAST



FY2024 Earnings Forecast | Summary



- FOREX impact and solid demand in Digital Workplace and Professional Print
- Industry: Restrained capital investment by customers and intensified competition for some applications in sensing, and a decrease in IT applications in performance materials
- Discontinued operation and gain from transfer through the business transfer of Precision Medicine
- Incorporation of use of third-party capital for non-focused businesses, business selection and concentration, and impairment loss risks for some businesses (¥-29.0 billion)
- Deterioration in finance income & loss, including foreign exchange loss

	FY23 ^{*1} Result	FY24 Previous forecast	FY24 Forecast	Change	[¥ billions] Discontinued operations (excluded)
Revenue	1,160.0	1,160.0	1134.0	-26.0	- 46.0
Business contribution profit	26.0	40.0	42.0	+2.0	+4.0
Operating Profit	26.1	13.0	-14.0	-27.0	+4.0
Profit attributable to owners of the Company	4.5	0.0	0.0	_	+41.0
Dividends (¥/share)	5	0	0	_	

					FOREX Se	nsitivity [¥ b
FOREX [Y	Yen]		6M	Full year ^{*2}	Revenue	Operating profit
	USD 144.62	140.00	152.63	3 146.32	+3.0	- 0.0
	EUR 156.80	150.00	165.95	5 157.97	+1.6	+0.4
	RMB 20.14	20.00	21.15	5 20.58	+3.2	+1.1

^{*1} Before retrospective adjustment of discontinued operations

^{*2} Average of actual rates for 6M and expected rates for H2 (USD: ¥140, EUR: ¥150, RMB: ¥20)

FY2024 Earnings Forecast | Revenue & Profit




Revenue	FY23 result	FY24 Previous forecast	FY24 Forecast	Change
Digital Workplace	614.9	600.0	620.0	+20.0
Professional Print	263.4	270.0	280.0	+10.0
Industry	123.6	136.0	126.0	- 10.0
Imaging Solutions	105.2	108.0	108.0	-
Precision Medicine	52.3	46.0	0.0	- 46.0
Corporate, etc.	0.7	0.0	0.0	_
Company overall	1,160.0	1,160.0	1,134.0	- 26.0

Business contribution profit	FY23 result	Ratio	FY24 Previous forecast	Ratio	FY24 Forecast	Ratio	Change
Digital Workplace	32.7	5%	33.5	6%	34.5	6%	+1.0
Professional Print	13.8	5%	16.5	6%	17.5	6%	+1.0
Industry	17.6	14%	22.0	16%	18.0	14%	- 4.0
Imaging Solutions	-8.4	-	-5.5	-	-5.5	-	-
Precision Medicine	-7.6	-	-4.0	-	0.0	-	+4.0
Corporate, etc.	-22.2	-	-22.5	-	-22.5	-	-
Company overall	26.0	2%	40.0	3%	42.0	4%	+2.0

Operating profit	FY23 result	Ratio	FY24 Previous forecast	Ratio	FY24 Forecast	Ratio	Change
Digital Workplace	33.0	5%	33.5	6%	15.0	2%	- 18.5
Professional Print	11.6	4%	16.5	6%	15.0	5%	- 1.5
Industry	16.6	13%	22.0	16%	19.0	15%	- 3.0
Imaging Solutions	-10.9	_	-5.5	-	-6.0	-	- 0.5
Precision Medicine	-1.7	_	-4.0	-	0.0		+4.0
Corporate, etc.	-22.5	_	-49.5	-	-57.0	-	- 7.5
Company overall	26.1	2%	13.0	1%	-14.0	-	- 27.0

Complete management reforms to achieve growth from FY2025 onwards





Toward dividends resumption in line with profit growth in FY25

TOWARD
ACHIEVING OUR
MATERIALITY
TARGETS




Initiatives to Achieve Material Issues



[Recycled material technology as growth seeds] Expand adoption by other companies' products

- Our recycled material "Matelier®" with high strength and flame retardance and ease of molding adopted for SATO*1's four label printer products
- Expected to achieve approx. 65% reduction in CO₂ emissions compared to conventional products in the parts where the material is used



Our Strengths

Formulation design of high PCR*2 materials and highquality injection molding that support industry top-class rate of recycled materials used in MFP

Achievement Award for the Development of Female Engineers

- Our DEI promotion department received an organizational award at the Achievement Award for the Development of Female Engineers*3 hosted by the Japan Association of Technology Executives
- Awarded because of the high evaluation for female ratio in technical personnel recruitment of over 30%, system that supports the female career development, achievement of male childcare leave ratio of 75%



^{*1} SATO Corporation

^{*2} PCR: Post-Consumer Recycled. Resource recovery through the collection of used products

^{*3} An award that recognizes the achievements of individuals and organizations that have made outstanding contributions to the development of female engineers, supported by the Gender Equality Bureau Cabinet Office, METI, MHLW, MLIT, and the MEXT © KONICA MINOLTA






APPENDIX

Some of the materials that had been disclosed on this presentation slides have been changed to disclosure on the website. You can download and check it from below.

https://www.konicaminolta.com/shared/changeable/investors/include/fr/pdf/2025/2025_2q_presentation_supplementary.xlsx



Giving Shape to Ideas © KONICA MINOLTA

Changes in Segment Information due to Organizational Changes (Repost)



Segmented into the main three areas of Business Technologies Business, Industry Business, and Imaging Solutions Business to strengthen the structure for accelerating the execution of Medium-term Business Plan

Before FY2023					
Digital Workplace Business	■ Office ■ DW-DX				
Professional Print Business	■ Production print■ Industrial print■ Marketing services				
Healthcare Business	■ Medical imaging ■ Precision medicine				
Industry Business	■ Sensing ■ Performance materials ■ IJ components ■ Optical components ■ Imaging-IoT solutions ■ Visual solutions				
Corporate, etc. (QOL solutions, FORXAI, Technology Development Headquarters, and other CO)					

After FY2024						
Business Technol-	Business Business Technol-	■ Office ■ DW-DX				
ogies Business	Professional Print Business	■ Production print■ Industrial print■ Marketing services				
Industry Business		■ Sensing ■ Performance materials ■ Inkjet components ■ Optical components				
Imaging Solutions Business		 Healthcare (formerly medical imaging) Imaging-IoT solutions, etc. (including QOL solutions and FORXAI) Visual solutions 				
Precision Me	edicine Business					
Corporate, etc. (Technology Development Headquarters, and other CO)						

Financial Result - Overview



						[# Dillions]
	FY23 6M	FY24 6M	YoY	FY23 Q2	FY24 Q2	YoY
Revenue	552.8	583.7	+6%	286.4	297.5	+4%
Gross Profit	237.2	260.7	+10%	125.3	134.3	+7%
Gross Profit ratio	42.9%	44.7%	+1.7pt	43.8%	45.1%	+1.4pt
SG & A	235.0	242.9	+3%	119.0	118.0	-1%
Business Contribution Profit	2.3	17.8	+679%	6.4	16.2	+154%
Business Contribution Profit ratio	0.4%	3.1%		2.2%	5.4%	
Other income and expenses	-1.5	-18.6	-	-1.2	-16.5	-
Operating Profit (loss)	0.8	-0.7	-	5.2	-0.3	-
Operating Profit ratio	0.1%	-		1.8%	-	
Finance income and costs	-4.4	-9.3	-	-3.1	-7.9	
Profit (loss) before tax	-3.7	-10.0	-	2.0	-8.2	-,
Profit before tax ratio	-	-		0.7%	-	
Profit attributable to owners of the Company	-4.5	-10.7	-	1.1	-7.3	-
Profit attributable to owners of the Company ratio	-	-	-	0.4%	-	_
EPS [Yen]	-9.09	-21.66		2.17	-14.70	
CAPEX	18.9	17.4		11.1	9.6	
Depreciation and Amortization Expenses *	27.1	26.2		13.8	13.0	
R&D expenses	32.5	30.8		16.4	15.5	
FCF	9.4	16.7		20.2	25.0	
Investment and lending	0.7	0.0		0.7	0.0	

^{*} IFRS16 right-of-use assets amortization expenses not included.





SG&A	FY23 6M	FY24 6M	YoY	FY23 Q2	FY24 Q2	YoY
Selling expenses - variable	22.3	22.7	+0.5	11.3	11.2	-0.1
R&D expenses	32.5	30.8	-1.7	16.4	15.5	-0.9
Personnel expenses	115.4	119.8	+4.3	58.6	58.1	-0.5
Others	64.7	69.6	+4.8	32.7	33.2	+0.5
SG&A total	235.0	242.9	+7.9	119.0	118.0	-0.9
	(w/o F	OREX YoY)	-4.6	(w/o F	-4.0	

Other Income & Expenses / Finance Income & Loss



Recorded business structure improvement expenses (brought forward) Recorded foreign exchange losses due to the yen appreciation

		FY23 6M	FY24 6M	YoY	FY23 Q2	FY24 Q2	YoY
Business Contributio	n Profit	2.3	17.8	+15.5	6.4	16.2	+9.8
Other income	Other income total	2.8	2.6	-0.2	1.3	-0.6	-1.9
Other expenses	Business structure improvement expenses	0.8	16.4	+15.6	0.2	13.4	+13.2
	Loss on sales and disposals of property, plant and equipment, and intangible assets	1.1	1.4	+0.4	0.8	0.8	-0.0
	Other expenses	2.4	3.3	+0.9	1.5	1.7	+0.2
	Other expenses total	4.3	21.2	+16.9	2.5	16.0	+13.4
Operating Profit		0.8	-0.7	-1.5	5.2	-0.3	-5.5
Finance income	Interest and dividend income	1.4	1.5	+0.1	0.7	0.7	+0.0
	Foreign exchange gain	0.8	-	-0.8	-	-	-
	Other	0.3	0.1	-0.2	0.3	0.0	-0.3
	Finance income total	2.5	1.6	-0.9	1.0	0.7	-0.3
Finance costs	Interest expenses	5.0	4.6	-0.4	2.6	2.2	-0.3
	Lease interest	1.4	1.5	+0.0	0.7	0.7	-0.0
	Foreign exchange loss	-	4.6	+4.6	0.7	5.4	+4.7
	Other	0.5	0.3	-0.2	0.1	0.2	+0.1
	Finance costs total	6.9	11.0	+4.1	4.1	8.6	+4.5
Profit before tax		-3.7	-10.0	-6.3	2.0	-8.2	-10.2
Income tax exper	nse (income)	0.8	0.7	-0.0	0.8	-1.1	-1.8
Profit for the period		-4.5	-10.7	-6.2	1.2	-7.1	-8.4

FOREX Impact on Revenue and Operating Profit



[FOREX:¥]

[Impact, Sensitivity: ¥ billions]

	FY23	FY24	YoY Impact		FX Sensitivity*2		
	6M	6M	Revenue	OP	Revenue	OP	
USD	141.00	152.63	+17.0	- 0.9	+3.0	- 0.0	
EUR	153.39	165.95	+9.3	+5.3	+1.6	+0.4	
GBP	177.49	195.46	+2.2	- 0.1	+0.2	+0.1	
European Currency*1	-	-	+12.5	+5.2	+2.3	+0.7	
RMB	19.75	21.15	+2.6	+1.2	+3.2	+1.1	
Others	-	-	+3.8	+0.8	-	-	
Exchange contract effect	-	-	-	+0.1	-	-	
Total	-	-	+35.8	+6.5	-	-	

^{*1} European currency: Currencies used in Europe including EUR/GBP *2 FOREX Sensitivity: FOREX impact at ¥1 change (annual)

Consolidated Statements of Cash Flows



	FY23 6M	FY24 6M
Profit (loss) before tax	-3.7	-10.0
Depreciation and amortization expenses	37.8	37.3
Increase/decrease in trade and other receivables ("-" is increase)	28.5	9.2
Increase/decrease in inventories ("-" is increase)	16.9	-2.7
Increase/decrease in trade and other payables ("-" is decrease)	-25.7	-0.6
Others	-21.7	-5.3
Cash flows from operating activities		27.8
Purchase of property, plant and equipment	-11.5	-12.5
Purchase of intangible assets	-9.0	-7.5
Purchase of investments in subsidiaries	-1.4	-0.3
Others	-0.7	9.3
Net cash provided by (used in) investing activities	-22.6	-11.0
Free cash flows	9.4	16.7

Consolidated Statements of Financial Position



Mar 2023 | Mar 2024 | Sep 2024 Cash and cash equivalents 180.6 127.1 107.5 Trade and other receivables 313.5 319.5 299.3 242.1 219.1 Inventories 216.2 Other current assets 41.4 41.8 47.3 Assets held for sale 36.7 12.0 **Total current assets** 777.6 744.2 682.3 Property, plant and equipment 289.1 282.2 279.7 Goodwill and intangible asseets 261.4 258.9 271.0 Othe non-current assets 88.2 90.6 100.6 **Total non-current assets** 636.2 643.8 641.7

Total assets

1,413.8 1,388.1 1,324.0

	Mar 2023	Mar 2024	Sep 2024
Trade and other payables	200.5	193.8	182.3
Bonds and borrowings	469.1	426.6	405.9
Lease liabilities	99.2	95.9	99.5
Othe liabilities	145.1	118.3	113.6
Total liabilities	913.9	834.7	801.3
Equity attributable to owners of the Company	487.4	539.8	508.0
Non-controlling interests	12.5	13.6	14.7
Total equity	499.9	553.4	522.7
Total liabilities and equity	1,413.8	1,388.1	1,324.0

	Mar 2023	Mar 2024	Sep 2024
Equity ratio (%)	34.5	38.9	38.4
Equity ratio for company rating (%)	37.9	42.4	42.1
D/E ratio	1.17	0.97	0.99

Quarterly Financial Results by Segments: Revenue



[¥ billions]

			FY23			FY2	1
[Revenue]	Q1	Q2	Q3	Q4	Total	Q1	Q2
Digital Workplace	143.3	151.2	156.1	164.3	614.9	152.0	155.6
Office	122.6	129.1	133.2	139.6	524.5	129.0	133.4
DW-DX	20.7	22.1	22.8	24.7	90.4	23.0	22.2
Professional Print	60.2	63.8	65.7	73.7	263.4	67.6	71.4
Production print	37.7	41.0	43.5	46.4	168.6	42.2	44.1
Industrial print	7.7	9.4	8.6	11.9	37.6	8.4	11.9
Marketing services	14.8	13.4	13.6	15.3	57.2	17.1	15.5
Industry	29.7	32.0	28.4	33.5	123.6	31.0	29.5
Sensing	9.1	9.8	9.9	10.6	39.4	8.8	9.3
Performance materials	11.4	12.8	8.5	12.2	44.8	13.1	10.7
IJ components	4.5	4.7	4.9	5.5	19.6	5.3	4.7
Optical components	4.7	4.8	5.1	5.2	19.7	3.7	4.8
Imaging Solutions	21.8	26.7	24.6	32.1	105.2	22.8	27.6
Healthcare	18.0	22.1	20.4	26.2	86.7	18.8	22.6
Imaging-IoT solutions, etc.	2.9	3.6	3.0	4.2	13.8	3.1	3.6
Visual solutions	0.8	1.0	1.1	1.7	4.7	0.9	1.4
Precision Medicine	11.3	12.4	14.3	14.3	52.3	12.6	13.3
Corporate, etc.	0.2	0.2	0.2	0.2	0.7	0.2	0.1
Company overall	266.4	286.4	289.2	318.0	1,160.0	286.2	297.5

*1)

Quarterly Financial Results by Segments: Profit



			FY23			FY24	1
[Business Contribution Profit]	Q1	Q2	Q3	Q4	Total	Q1	Q2
Digital Workplace	2.4	8.4	9.7	12.2	32.7	6.8	12.3
Professional Print	0.8	2.8	5.2	5.0	13.8	1.8	4.8
*1) Industry	3.9	4.3	4.4	5.1	17.6	3.8	3.8
*2) Imaging Solutions	-2.7	-0.8	-2.9	-2.0	-8.4	-4.0	-0.9
Precision Medicine	-2.9	-2.1	-1.1	-1.5	-7.6	-0.2	1.6
*3) Corporate, etc.	-5.5	-6.3	-5.4	-5.1	-22.2	-6.5	-5.3
Company overall	-4.1	6.4	9.9	13.8	26.0	1.6	16.2
							_
[Operating Profit]	Q1	Q2	Q3	Q4	Total	Q1	Q2
Digital Workplace	2.0	8.0	9.6	13.3	33.0	4.5	2.1
Professional Print	0.9	2.7	5.1	2.8	11.6	1.7	3.3
*1) Industry	3.9	3.7	4.4	4.6	16.6	3.1	4.1
*2) Imaging Solutions	-2.7	-0.8	-4.7	-2.6	-10.9	-4.3	-1.7
Precision Medicine	-3.1	-2.1	-1.1	4.6	-1.7	1.4	-1.2
*3) Corporate, etc.	-5.4	-6.4	-5.6	-5.1	-22.5	-6.8	-7.0
Company overall	-4.4	5.2	7.8	17.5	26.1	-0.4	-0.3

^{*1)} Industry Business: Sensing, performance materials, IJ components, optical components, industry business development center, industry business strategy office


^{*2)} Imaging Solutions Business: Healthcare(former medical imaging), imaging-IoT solutions, etc.(incl. QOL solutions, FORXAI), visual solutions

^{*3)} Corporate, etc.: Technical development headquarters, other corporate

(Repost from FY2023 Industry Business Briefing Session) Product Map by Wavelength and Future Growth Steps









Our products

^{*1} Wavelength range of light sources. As the wavelength becomes shorter in the order of VIS(visible), UV(ultraviolet), DUV(deep ultraviolet), VUV(vacuum ultraviolet), it is used for forming and inspecting, etc. finer semiconductor circuit patterns.

FY24 Quarterly Performance | Hard and Non-hard Revenue YoY








Revenue and KPI Trends of Genetic Testing





Indexed with FY2019 Q1 as 100 / Revenue is JPY basis.

38

^{*}Before reduction of recoverable amount of accounts receivable and revenue



Cautionary Statement:

The forecasts mentioned in this material are the results of estimations based on currently available information, and accordingly, contain risks and uncertainties. The actual results of business performance may sometimes differ from those forecasts due to various factors.

Remarks:

Yen amounts are rounded to the nearest 100 million.